NAS:LOXO (USA) Also trade in: Germany

Loxo Oncology Inc

$ 234.66 0 (0%)
Volume: 0 Avg Vol (1m): 0
Market Cap $: 7.22 Bil Enterprise Value $: 6.59 Bil
P/E (TTM): 0.00 P/B: 18.92
Earnings Power Value 20.78
Net Current Asset Value 11.39
Tangible Book 12.41
Projected FCF 0
Median P/S Value 247.86
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
73.10% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
LOXO: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.58
Equity-to-Asset ranked lower than
66.19% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
LOXO: 0.58
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: 0.48, Med: 0.53, Max: 0.58
Current: 0.58
0.48
0.58
Interest Coverage No Debt
Interest Coverage ranked higher than
67.40% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
LOXO: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 15.49
DISTRESS
GREY
SAFE

Profitability & Growth : 4/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -50.33
Operating Margin ranked lower than
53.03% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
LOXO: -50.33
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -715.47, Med: -715.47, Max: -50.33
Current: -50.33
-715.47
-50.33
Net Margin % -43.49
Net Margin ranked lower than
52.15% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
LOXO: -43.49
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -698.95, Med: -698.95, Max: -43.49
Current: -43.49
-698.95
-43.49
ROE % -16.33
ROE ranked higher than
59.56% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
LOXO: -16.33
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -58.57, Med: -45.64, Max: -16.33
Current: -16.33
-58.57
-16.33
ROA % -9.49
ROA ranked higher than
64.76% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
LOXO: -9.49
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -47.82, Med: -32, Max: -9.49
Current: -9.49
-47.82
-9.49
ROC (Joel Greenblatt) % -3424.17
ROC (Joel Greenblatt) ranked lower than
84.27% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
LOXO: -3424.17
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -344833.33, Med: -57854.17, Max: -3424.17
Current: -3424.17
-344833.33
-3424.17
3-Year Total EBITDA Growth Rate -94.50
3-Year EBITDA Growth Rate ranked lower than
74.44% of 802 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 4.6, Min: -2038.5
LOXO: -21.2
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
3-Year EBITDA Growth Rate range over the past 10 years
Min: 0, Med: -10.6, Max: -21.2
Current: -21.2
0
-21.2
3-Year EPS w/o NRI Growth Rate -20.20
3-Year EPS w/o NRI Growth Rate ranked lower than
75.49% of 763 companies
in the Biotechnology industry.
Industry Max: 1406.7, Med: 5.7, Min: -2103.4
LOXO: -20.2
Ranked among companies with meaningful 3-Year EPS w/o NRI Growth Rate only.
3-Year EPS w/o NRI Growth Rate range over the past 10 years
Min: 0, Med: -10.1, Max: -20.2
Current: -20.2
0
-20.2

» LOXO's 30-Y Financials

Financials (Next Earnings Date: 2019-08-09)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:LOXO

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare HKSE:06160 NAS:JAZZ NAS:NBIX SZSE:002252 NAS:TECH NAS:BLUE TSE:4587 SZSE:000661 NAS:AMRN XAMS:GLPG NAS:MRNA NAS:EXEL SZSE:002007 NAS:SAGE NAS:NKTR NAS:SRPT NAS:ASND BOM:532523 SZSE:300347 NAS:ALNY
Traded in other countries L95.Germany
Address
Loxo Oncology Inc develops medicines for patients with genetically defined cancers. Its approach is based on the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building inhibitors against single targets in the cancer cell. Its pipeline of products includes Larotrectinib, Loxo etc.

Ratios

Current vs industry vs history
Price-to-Owner-Earnings 36.30
Price-to-Owner-Earnings ranked lower than
100.00% of 145 companies
in the Biotechnology industry.
Industry Max: 305714.29, Med: 34.35, Min: 0.21
LOXO: 36.3
Ranked among companies with meaningful Price-to-Owner-Earnings only.
Price-to-Owner-Earnings range over the past 10 years
Min: 19.77, Med: 24.83, Max: 36.3
Current: 36.3
19.77
36.3
PB Ratio 18.92
PB Ratio ranked lower than
84.82% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
LOXO: 18.92
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 6.1, Med: 12.34, Max: 18.92
Current: 18.92
6.1
18.92
PS Ratio 48.93
PS Ratio ranked lower than
77.27% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
LOXO: 48.93
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 26.65, Med: 51.68, Max: 160.21
Current: 48.93
26.65
160.21
Price-to-Free-Cash-Flow 30.36
Price-to-Free-Cash-Flow ranked higher than
67.11% of 152 companies
in the Biotechnology industry.
Industry Max: 5923, Med: 37.07, Min: 0.04
LOXO: 30.36
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
Price-to-Free-Cash-Flow range over the past 10 years
Min: 13.88, Med: 21.51, Max: 34.39
Current: 30.36
13.88
34.39
Price-to-Operating-Cash-Flow 29.84
Price-to-Operating-Cash-Flow ranked higher than
63.33% of 210 companies
in the Biotechnology industry.
Industry Max: 23050, Med: 29.99, Min: 0.04
LOXO: 29.84
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
Price-to-Operating-Cash-Flow range over the past 10 years
Min: 13.8, Med: 21.21, Max: 34.12
Current: 29.84
13.8
34.12
EV-to-EBIT -90.49
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
LOXO: -90.49
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -90.49, Med: -38.4, Max: -11
Current: -90.49
-90.49
-11
EV-to-EBITDA -91.04
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
LOXO: -91.04
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -91.04, Med: -38.5, Max: -11
Current: -91.04
-91.04
-11
EV-to-Revenue 45.54
EV-to-Revenue ranked lower than
71.85% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
LOXO: 45.54
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: 22.6, Med: 45.1, Max: 130.9
Current: 45.54
22.6
130.9
Current Ratio 3.62
Current Ratio ranked lower than
57.91% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
LOXO: 3.62
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 3.52, Med: 33.96, Max: 165.11
Current: 3.62
3.52
165.11
Quick Ratio 3.62
Quick Ratio ranked lower than
54.47% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
LOXO: 3.62
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 3.52, Med: 33.96, Max: 165.11
Current: 3.62
3.52
165.11

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate -21.70
3-Year Share Buyback Rate ranked lower than
64.53% of 857 companies
in the Biotechnology industry.
Industry Max: 43.5, Med: -13.4, Min: -1815.4
LOXO: -21.7
Ranked among companies with meaningful 3-Year Share Buyback Rate only.
3-Year Share Buyback Rate range over the past 10 years
Min: -21.7, Med: -10.85, Max: 0
Current: -21.7
-21.7
0

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 18.91
Price-to-Tangible-Book ranked lower than
78.64% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
LOXO: 18.91
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 1.73, Med: 3.71, Max: 18.92
Current: 18.91
1.73
18.92
Price-to-Median-PS-Value 0.95
Price-to-Median-PS-Value ranked higher than
66.52% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
LOXO: 0.95
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.69, Med: 1.06, Max: 2.29
Current: 0.95
0.69
2.29
Earnings Yield (Joel Greenblatt) % -1.11
Earnings Yield (Greenblatt) ranked higher than
65.40% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
LOXO: -1.11
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -9.1, Med: -2.6, Max: -1.1
Current: -1.11
-9.1
-1.1

More Statistics

Revenue (TTM) (Mil) $ 144.8
EPS (TTM) $ -2.03
Beta 0
Volatility % 78.38
52-Week Range $ 101.7 - 234.93
Shares Outstanding (Mil) 30.75

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA N
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y